Garenoxacin (GRNX), 400 mg/day, was administered to 72 acute bacterial sinusitis patients who were experiencing large amounts of purulent postnasal drip, and for whom penicillin antimicrobial agents had proven to be ineffective. The utility of this treatment regimen was then examined. The improvement rates in the subjective and objective symptoms were 85% and 87%, respectively, thus indicating an excellent degree of effectiveness. In addition, the improvement rate in the sinus roentgen findings was 68%. A bacteriological study detected 91 strains, of which 10 strains (11%) were
S. pneumoniae and 59 strains (65%) were
H. influenzae. Adverse reactions were observed in a total of two patients (2%): one patient manifested diarrhea while another patient experienced Candida vaginitis. The main causative agent for acute bacterial sinusitis, for which penicillin antimicrobial agents were ineffective, was
H. influenzae. As a result, GRNX was confirmed to have a high effectiveness against this disease as a second line agent.
View full abstract